Appendix

Appendix Exhibit 1: Distribution Of Cost-effectiveness Ratios Across Specialty And Traditional Drugs

- **Dominant**
- $0 to <$25,000
- $25,000 to <$50,000
- $50,000 to <$100,000
- $100,000 to <$150,000
- $150,000 to <$200,000
- $200,000 to <$250,000
- $250,000 to <$300,000
- ≥$300,000

**SOURCE** Authors’ analysis. **NOTES** One drug, Natalizumab (Tysabri®), was associated with comparative effectiveness studies that did not report incremental costs. Thirteen drugs were both less expensive and less costly, and their ICERs were not included in this figure. “Dominant” and “Dominated” are explained in the text and in Exhibit 1.
Chambers JD, Thorat T, Pyo J, Chenoweth M, Neumann PJ. Despite high costs, specialty drugs may offer value for money comparable to that of traditional drugs. Health Aff (Millwood). 2014;33(10).

Appendix - Reference List for Exhibit 4: Fifteen Drugs With The Largest Incremental Quality-Adjusted Life-Year (QALY) Gains Over Preexisting Care

(b) Deferasirox (Exjade)


(c) Imatinib mesylate (Gleevec)


(d) Linezolid (Zyvox)


(e) Ranibizumab (Lucentis)


Chambers JD, Thorat T, Pyo J, Chenoweth M, Neumann PJ. Despite high costs, specialty drugs may offer value for money comparable to that of traditional drugs. Health Aff (Millwood). 2014;33(10).


(f) Bosentan (Tracleer)


(g) Oxaliplatin (Eloxatin)


(h) Dasatinib (Sprycel)
Despite high costs, specialty drugs may offer value for money comparable to that of traditional drugs. Health Aff (Millwood). 2014;33(10).


(i) Enfuvirtide (Fuzeon)


(j) Entecavir (Baraclude)


(k) Agalsidase beta (Fabrazyme)


(l) Adefovir dipivoxil (Hepsera)
Chambers JD, Thorat T, Pyo J, Chenoweth M, Neumann PJ. Despite high costs, specialty drugs may offer value for money comparable to that of traditional drugs. Health Aff (Millwood). 2014;33(10).


(m) Lanthanum carbonate (Fosrenol)


(n) Drotrecogin alfa (Xigris)


(o) Epirubicin hydrochloride (Ellence)


(p) Peginterferon alfa-2b (Pegintron)


Chambers JD, Thorat T, Pyo J, Chenoweth M, Neumann PJ. Despite high costs, specialty drugs may offer value for money comparable to that of traditional drugs. Health Aff (Millwood). 2014;33(10).


Appendix - Reference List for Exhibit 5: Fifteen Drugs With The Largest Additional Costs Over Preexisting Care

(b) Agalsidase beta (Fabrazyme)


(c) Deferasirox (Exjade)


(d) Imatinib mesylate (Gleevec)


(e) Omalizumab (Xolair)


(f) Dasatinib (Sprycel)
Chambers JD, Thorat T, Pyo J, Chenoweth M, Neumann PJ. Despite high costs, specialty drugs may offer value for money comparable to that of traditional drugs. Health Aff (Millwood). 2014;33(10).


(g) **Crizotinib (Xalkori)**


(h) **Cabazitaxel (Jevtana Kit)**


(i) **Enfuvirtide (Fuzeon®)**


(j) **Ranibizumab (Lucentis)**


Chambers JD, Thorat T, Pyo J, Chenoweth M, Neumann PJ. Despite high costs, specialty drugs may offer value for money comparable to that of traditional drugs. Health Aff (Millwood). 2014;33(10).


(k) Fingolimod (Gilenya)


(l) Cetuximab (Erbitux)


(m) Abatacept (Orencia)


(n) Temsirolimus (Torisel)

Chambers JD, Thorat T, Pyo J, Chenoweth M, Neumann PJ. Despite high costs, specialty drugs may offer value for money comparable to that of traditional drugs. Health Aff (Millwood). 2014;33(10).


(o) Cinacalcet Hydrochloride (Sensipar)


(p) Ambrisentan (Letairis)